- Each component assayed to ≥99% (HPLC), documented per lot
- Certificate of analysis tied to your lot number
- Tracked EU delivery, dispatched the next working day
Retatrutide + Cagrilintide
15 mg co-formulated vial combining a triple incretin agonist and an amylin analogue
In stock1 format available
€204
This listing is currently unavailable. Contact us and we will tell you when it is back or suggest an equivalent.
Ask about this listing or request its COA- FormLyophilized powder, sealed glass vial
- Research areasIncretin and amylin receptor signalling, energy balance, metabolic models
For laboratory research use only. Sold exclusively for in-vitro laboratory research by qualified professionals. Not for human or veterinary use, and not a medicine, food, cosmetic or dietary supplement. Terms and Conditions
Overview
Key facts
This vial combines two of the metabolic peptides that have attracted the most research in the past ten years.
- Purity
- ≥99% by HPLC per component; lot-matched COA
- Form
- Lyophilized powder, sealed glass vial
- Storage
- −20 °C, protected from light and moisture
- Available size
- 15 mg · (12.5/2.5)
For research use only. Not for human consumption.
This vial combines two of the metabolic peptides that have attracted the most research in the past ten years. Retatrutide is a synthetic analogue of 39 residues engineered to activate three receptors together — those for GIP, GLP-1 and glucagon — and a fatty side chain keeps it in circulation for longer. Cagrilintide is a long-lasting analogue of amylin, a hormone the pancreas releases alongside insulin, and acts through populations of amylin and calcitonin receptors.
Peptide Medix EU delivers the blend freeze-dried in a sealed glass vial. Each of the two components is HPLC-assayed to ≥99% purity, and the lot is released with its own certificate of analysis; as both peptides are big and structurally complex, the certificate reports each of them separately. The product is a research chemical intended solely for laboratory studies. It is not a medicine, has no authorisation for any use in people, and comes without any dosing information.
What sets this listing apart
Retatrutide + Cagrilintide combines Retatrutide and Cagrilintide in one listing (15 mg). Components that are also sold on their own are linked below, each with its own specification and COA.
Same compound, other listings
Specifications
Supply & purity
- Form
- Lyophilized powder, sealed glass vial
- Purity
- ≥99% by HPLC per component; lot-matched COA
- Solubility
- Bacteriostatic water; add slowly and avoid agitation
Handling & storage
- Storage (lyophilized)
- −20 °C, protected from light and moisture
- Storage (reconstituted)
- 2–8 °C, protected from light
Additional detail
- Product type
- Two-peptide metabolic research blend, single vial
- Components
- Retatrutide (LY3437943) and cagrilintide (AM833)
- Total peptide content
- 15 mg per vial — retatrutide 12.5 mg, cagrilintide 2.5 mg
- Retatrutide
- CAS 2381089-83-2 · C221H342N46O68 · 4731.30 g/mol
- Cagrilintide
- CAS 1415456-99-3 · C194H309N55O59S2 · 4409.07 g/mol
- Retatrutide class
- GIP / GLP-1 / glucagon triple receptor agonist, 39 residues
- Cagrilintide class
- Long-acting amylin and calcitonin receptor agonist, 32 residues
- Research areas
- Incretin and amylin receptor signalling, energy balance, metabolic models
Questions about Retatrutide + Cagrilintide
In what ratio are the peptides present?
12.5 mg of retatrutide and 2.5 mg of cagrilintide — 15 mg in total, split 5:1 by weight. Their molecular weights are close (about 4,731 g/mol for retatrutide and 4,409 g/mol for cagrilintide), so in moles the ratio ends up almost the same as by weight.
What is the reason for pairing an incretin agonist with an amylin analogue?
The two act on different receptor families: retatrutide on GIP, GLP-1 and glucagon receptors, cagrilintide on amylin and calcitonin receptors. Studies that want both signalling arms in one preparation use a co-formulation instead of two vials.
Does the COA cover each component separately?
Yes. Because the vial contains two peptides, the lot certificate states HPLC identity and purity for retatrutide and for cagrilintide individually, not as one combined figure. We can send you the latest version before you order.
Can I change the ratio between the two?
Not from this vial — combining them fixes the split at 12.5 mg to 2.5 mg. If your study needs to change the amount of one peptide independently, use retatrutide and cagrilintide from separate vials; Peptide Medix EU stocks both on their own, in several sizes.
